PROCEPT BioRobotics (PRCT) News Today

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares have decreased as investors absorb a wave of securities-fraud class-action notices and law-firm solicitations. The litigation introduces potential financial, legal and reputational risks for the company.

• Negative Sentiment: A federal securities class action has been filed on behalf of investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026. Investors have until September 22, 2026 to seek appointment as lead plaintiff. Kaplan Fox class action notice
• Negative Sentiment: The allegations reportedly center on weaker-than-expected unit handpiece sales, excess customer inventory and repeated late-quarter bulk discounts. The complaint also challenges company explanations that revenue volatility was caused by temporary saline shortages. Hagens Berman investor alert
• Negative Sentiment: Multiple law firms, including Robbins Geller, Bragar Eagel & Squire, Pomerantz, SBS Law and Bernstein Liebhard, issued substantially similar investor alerts. The volume of announcements may amplify uncertainty around PROCEPT’s sales practices, demand outlook and potential litigation costs. Robbins Geller investor deadline notice

The reports describe allegations and legal claims, not proven wrongdoing. However, the concentration of notices within the past two days is likely weighing on sentiment, particularly because PROCEPT remains unprofitable and recently reported an earnings-per-share loss. Investors will be watching for the company’s response, developments in the lawsuit and any effect on future handpiece sales and revenue.